ST. LOUIS, March 18, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the first patients treated with the Niobe® ES remote magnetic navigation system at the Centre Hospitalier Régional Universitaire de Nancy (CHRU of Nancy) in France. CHRU of Nancy is recognized as a pioneer of electrophysiology (EP) ablations in France, performing more than 900 procedures annually, and represents the fourth institution in the country to implement the Niobe system.
“With an innovative design, the Niobe system has been shown to increase the accuracy of catheter navigation, improve the quality of the cardiac 3D mapping, reduce complications and radiation exposure, and decrease operator fatigue. We are also excited to use the automation features of the Niobe system to effectively ablate diseased tissue in a reliable and reproducible manner and look forward to the release of enhancements currently under development,” said Professor Etienne Aliot, Chief of Cardio Medical Surgery at CHRU of Nancy. “The acquisition of the Niobe system at CHRU of Nancy will advance our EP program, especially in the treatment of ventricular tachycardia (VT), a highly complicated procedure on which we have placed considerable emphasis, and continue to strengthen our regional and national leadership in terms of cardiac rhythm management.”
Professor Aliot was instrumental in bringing the Niobe system to CHRU of Nancy, along with Professor Nicolas Sadoul, Director of Cardiology, and Professor Christian Chillou, who leads the Heart Rhythm Unit and is one of the leading VT specialists in Europe. In addition to strengthening treatment, the Niobe system will enable CHRU of Nancy to collaborate with other hospitals to develop the best practices for the purpose of training new physicians. CHRU of Nancy is one of the few institutions in France to be named a European Training Center by the European Hearth Rhythm Society.
Read French Version
About CHRU of Nancy
CHRU of Nancy has nine hospitals on two sites, providing treatment options for more than 700,000 patients annually and training health professionals engaged at all levels of public health, screening, prevention and education. The Lorraine Institute of the Heart and Vessels Louis Mathieu, the newest building at the Brabois site of CHRU of Nancy, brings together all units of the cardiovascular division, including the Heart Rhythm Unit.
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management solutions, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, the European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its continued listing on the NASDAQ Capital Market, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
STXS Company Contact:
Chief Financial Officer
STXS Investor Contact:
Todd Kehrli / Jim ByersMKR Group, Inc.